Catheter-based plasmid-mediated transfer of genes into ischemic myocardium using the pCOR plasmid

Background Direct transfer of genes holds promise for the sustained delivery of therapeutic proteins to treat cardiovascular diseases. This can be accomplished by several approaches, including use of adenoviral vectors and naked plasmid DNA vectors. We previously demonstrated achieval of effective delivery of genes into the myocardium with a left ventricular-guided catheter-based approach using an adenoviral vector, Objective To evaluate the levels and duration of expression of genes induced after injection of a specific plasmid vector, using the same delivery platform as that in our previous work, Methods The pCOR plasmids are narrow-host-range plasmid vectors designed for nonviral gene therapy. We tested the ability of the pCOR plasmid vector to express its transgene after injection into the myocardium of pigs with chronic experimental ischemia using a catheter-based transendocardial delivery system. Four animals were subjected to transendocardial injections of the luciferase reporter pCOR gene into ischemic and nonischemic zones using the Biosense intramyocardial injection catheter. Injections (1 mg per animal, 50 mug per injection site) were performed at 20 sites in ischemic and nonischemic zones. Measurements of luciferase activity were performed 3 and 7 days thereafter. Results We observed high levels of expression of luciferase gene in ischemic and nonischemic regions ton days 3 and 7, respectively, in ischemic zone 58 237 and 33 709 pg; in nonischemic zone 39 928 and 46 036 pg), Control noninjected samples from the left and right ventricles contained no detectable luciferase activity. Conclusions With a catheter-based approach, the pCOR plasmid was successfully used to deliver genes into designated myocardial regions, and provides sustained expression of protein for at least 7 days, of roughly similar magnitudes in ischemic and nonischemic myocardium. Coron Artery Dis 11:615-619 (C) 2000 Lippincott Williams & Wilkins.